Publications

Sort by: Author Title Type [ Year  (Desc)]
2017
Mendes, Rita, Pedro Pedrosa, Joao C. Lima, Alexandra R. Fernandes, and Pedro V. Baptista. "Photothermal enhancement of chemotherapy in breast cancer by visible irradiation of Gold Nanoparticles." Scientific Reports 7 (2017). Abstract

n/a

Pedrosa, Pedro, Amelie Heuer-Jungemann, Antonios G. Kanaras, Alexandra R. Fernandes, and Pedro V. Baptista. "Potentiating angiogenesis arrest in vivo via laser irradiation of peptide functionalised gold nanoparticles." Journal of Nanobiotechnology 15 (2017). Abstract

n/a

Veigas, Bruno, Joana Pinto, Raquel Vinhas, Tomas Calmeiro, Rodrigo Martins, Elvira Fortunato, and Pedro Viana Baptista. "Quantitative real-time monitoring of RCA amplification of cancer biomarkers mediated by a flexible ion sensitive platform." Biosensors & Bioelectronics 91 (2017): 788-795. Abstract

n/a

Roma-Rodrigues, Catarina, Francisca Pereira, Antonio P. Alves de Matos, Marta Fernandes, Pedro V. Baptista, and Alexandra R. Fernandes. "Smuggling gold nanoparticles across cell types - A new role for exosomes in gene silencing." Nanomedicine-Nanotechnology Biology and Medicine 13 (2017): 1389-1398. Abstract

n/a

Raposo, L. R., C. Roma-Rodrigues, J. Jesus, L. M. D. R. S. Martins, A. J. Pombeiro, P. V. Baptista, and A. R. Fernandes. "Targeting canine mammary tumours via gold nanoparticles functionalized with promising Co(II) and Zn(II) compounds." Veterinary and Comparative Oncology 15 (2017): 1537-1542. Abstract

n/a

2016
Cordeiro, Milton, Leticia Giestes, Joao Carlos Lima, and Pedro Baptista. "BioCode gold-nanobeacon for the detection of fusion transcripts causing chronic myeloid leukemia." Journal of Nanobiotechnology 38 (2016). AbstractWebsite

Background
Gold-nanobeacons (Au-nanobeacons) have proven to be versatile systems for molecular diagnostics and therapeutic actuators. Here, we present the development and characterization of two gold nanobeacons combined with Förster resonance energy transfer (FRET) based spectral codification for dual mode sequence discrimination. This is the combination of two powerful technologies onto a single nanosystem.

Results
We proved this concept to detect the most common fusion sequences associated with the development of chronic myeloid leukemia, e13a2 and e14a2. The detection is based on spectral shift of the donor signal to the acceptor, which allows for corroboration of the hybridization event. The Au-nanobeacon acts as scaffold for detection of the target in a homogenous format whose output capability (i.e. additional layer of information) is potentiated via the spectral codification strategy.

Conclusions
The spectral coded Au-nanobeacons permit the detection of each of the pathogenic fusion sequences, with high specificity towards partial complementary sequences. The proposed BioCode Au-nanobeacon concept provides for a nanoplatform for molecular recognition suitable for cancer diagnostics.

Vinhas, Raquel, Milton Cordeiro, Pedro Pedrosa, Alexandra R. Fernandes, and Pedro V. Baptista. "Current trends in molecular diagnostics of chronic myeloid leukemia." Leukemia & Lymphoma (2016): 1-14. AbstractWebsite

Nearly 1.5 million people worldwide suffer from chronic myeloid leukemia (CML), characterized by the genetic translocation t(9;22)(q34;q11.2), involving the fusion of the Abelson oncogene (ABL1) with the breakpoint cluster region (BCR) gene. Early onset diagnosis coupled to current therapeutics allow for a treatment success rate of 90, which has focused research on the development of novel diagnostics approaches. In this review, we present a critical perspective on current strategies for CML diagnostics, comparing to gold standard methodologies and with an eye on the future trends on nanotheranostics.

Conde, Joao, Furong Tian, Jesus M. de la Fuente, and Pedro V. Baptista. "Editorial: Cancer Nanotheranostics: What Have We Learned So Far?" Frontiers in Chemistry 71 (2016).Website
Cordeiro, Mílton, Fábio Ferreira Carlos, Pedro Pedrosa, António Lopez, and Pedro Viana Baptista. "Gold Nanoparticles for Diagnostics: Advances towards Points of Care." Diagnostics 6 (2016): 43. AbstractWebsite

The remarkable physicochemical properties of gold nanoparticles (AuNPs) have prompted developments in the exploration of biomolecular interactions with AuNP-containing systems, in particular for biomedical applications in diagnostics. These systems show great promise in improving sensitivity, ease of operation and portability. Despite this endeavor, most platforms have yet to reach maturity and make their way into clinics or points of care (POC). Here, we present an overview of emerging and available molecular diagnostics using AuNPs for biomedical sensing that are currently being translated to the clinical setting.

Corvo, Luísa M., Ana Soraia Mendo, Sara Figueiredo, Rogério Gaspar, Miguel Larguinho, Fátima Guedes M. C. da Silva, Pedro Viana Baptista, and Alexandra R. Fernandes. "Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy." Pharmaceutical Research (2016).
Ma, Zhen, Bian Zhang, Fátima Guedes M. C. da Silva, Joana Silva, Ana Soraia Mendo, Pedro Viana Baptista, and Alexandra R. Fernandes. "Synthesis, Characterization, Thermal Properties and Antiproliferative Potential of Copper(II) 4′-phenyl-terpyridine Compounds." Dalton Transactions 45 (2016).
Vinhas, Raquel, Claudia Correia, Patricia Ribeiro, Alexandra Lourenco, Aida Botelho de Sousa, Alexandra R. Fernandes, and Pedro V. Baptista. "Colorimetric assessment of BCR-ABL1 transcripts in clinical samples via gold nanoprobes." Analytical and Bioanalytical Chemistry 408 (2016): 5277-5284. Abstract

n/a

Cordeiro, Milton, Fabio Ferreira Carlos, Pedro Pedrosa, Antonio Lopez, and Pedro Viana Baptista. "Gold Nanoparticles for Diagnostics: Advances towards Points of Care." Diagnostics 6 (2016). Abstract

n/a

Lenis-Rojas, O. A., A. R. Fernandes, C. Roma-Rodrigues, P. V. Baptista, F. Marques, D. Perez-Fernandez, J. Guerra-Varela, L. Sanchez, D. Vazquez-Garcia, M. Lopez Torres, A. Fernandez, and J. J. Fernandez. "Heteroleptic mononuclear compounds of ruthenium(II): synthesis, structural analyses, in vivo antitumor activity and in vivo toxicity on zebrafish embryost." Dalton Transactions 45 (2016): 19127-19140. Abstract

n/a

Martins, Marta, Pedro V. Baptista, Ana Soraia Mendo, Claudia Correia, Paula Videira, Antonio S. Rodrigues, J. Muthukumaran, Teresa Santos-Silva, Ana Silva, Fatima M. C. Guedes da Silva, Joana Gigante, Antonio Duarte, Malgorzata Gajewska, and Alexandra R. Fernandes. "In vitro and in vivo biological characterization of the anti-proliferative potential of a cyclic trinuclear organotin(IV) complex." Molecular Biosystems 12 (2016): 1015-1023. Abstract

n/a

Roma-Rodrigues, Catarina, Cynthia Alves-Barroco, Luis R. Raposo, Mafalda N. Costa, Elvira Fortunato, Pedro Viana Baptista, Alexandra R. Fernandes, and Ilda Santos-Sanches. "Infection of human keratinocytes by Streptococcus dysgalactiae subspecies dysgalactiae isolated from milk of the bovine udder." Microbes and Infection 18 (2016): 290-293. Abstract

n/a

Luisa Corvo, M., Ana Soraia Mendo, Sara Figueiredo, Rogerio Gaspar, Miguel Larguinho, Fatima M. C. Guedes da Silva, Pedro Viana Baptista, and Alexandra R. Fernandes. "Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy." Pharmaceutical Research 33 (2016): 1351-1358. Abstract

n/a

Mendes, Rita, Barbara Carreira, Pedro V. Baptista, and Alexandra R. Fernandes. "Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology." Expert Review of Precision Medicine and Drug Development 1 (2016): 155-168. Abstract

n/a

Vinhas, Raquel, Anna Tolmatcheva, Rafaela Canto, Patricia Ribeiro, Alexandra Lourenco, Aida Botelho de Sousa, Pedro V. Baptista, and Alexandra R. Fernandes. "A novel mutation in CEBPA gene in a patient with acute myeloid leukemia." Leukemia & Lymphoma 57 (2016): 711-713. Abstract

n/a

Roma-Rodrigues, Catarina, Amelie Heuer-Jungemann, Alexandra R. Fernandes, Antonios G. Kanaras, and Pedro V. Baptista. "Peptide-coated gold nanoparticles for modulation of angiogenesis in vivo." International Journal of Nanomedicine 11 (2016): 2633-2639. Abstract

n/a

Baptista, Pedro Viana. "Precision nanomedicine in cancer: how far are we from personalization?" Expert Review of Precision Medicine and Drug Development 1 (2016): 227-228. Abstract

n/a

2015
Conde, João, Alfredo Ambrosone, Yulán Hernandez, Furong Tian, Mark McCully, Catherine C. Berry, Pedro V. Baptista, and Claudia T. " 15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics." NANO TODAY In Press (2015). Abstract

RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to down-regulate specific gene expression in diseased cells; opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the "do's and dont's" of the inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15.

Mendo, Ana Soraia, Sara Figueiredo, Catarina Roma-Rodrigues, Paula A. Videira, Zhen Ma, Mário Diniz, Miguel Larguinho, Pedro Costa, João C. Lima, Armando J. L. Pombeiro, Pedro V. Baptista, and Alexandra R. Fernandes. "Characterization of antiproliferative potential and biological targets of a copper compound containing 4'-phenyl terpyridine." JBIC Journal of Biological Inorganic Chemistry 2 (2015): 935-948. AbstractWebsite

Several copper complexes have been assessed as anti-tumor agents against cancer cells. In this work, a copper compound [Cu(H2O){OS(CH3)2}L](NO3)2 incorporating the ligand 4'-phenyl-terpyridine antiproliferative activity against human colorectal, hepatocellular carcinomas and breast adenocarcinoma cell lines was determined, demonstrating high cytotoxicity. The compound is able to induce apoptosis and a slight delay in cancer cell cycle progression, probably by its interaction with DNA and induction of double-strand pDNA cleavage, which is enhanced by oxidative mechanisms. Moreover, proteomic studies indicate that the compound induces alterations in proteins involved in cytoskeleton maintenance, cell cycle progression and apoptosis, corroborating its antiproliferative potential.

Pedrosa, Pedro, and Pedro Viana Baptista. "Gold and silver nanoparticles for diagnostics of infection." In Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases, edited by Mahendra Rai and Kateryna Kon, 1-18. Elsevier, 2015. Abstract

Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases delivers comprehensive coverage of the application of nanotechnology to pressing problems in infectious disease.
This text equips readers with cutting-edge knowledge of promising developments and future prospects in nanotechnology, paying special attention to microbes that are now resistant to conventional antibiotics, a concerning problem in modern medicine.
Readers will find a thorough discussion of this new approach to infectious disease treatment, including the reasons nanotechnology presents a promising avenue for the diagnosis, treatment, and prophylaxis of infectious diseases.

Vinhas, Raquel, Milton Cordeiro, Fábio Carlos, Soraia Mendo, Alexandra Fernandes, Sara Figueiredo, and Pedro Baptista. "Gold nanoparticle-based theranostics: disease diagnostics and treatment using a single nanomaterial." Journal of Nanobiosensors in Disease Diagnosis (2015): 11-23. AbstractWebsite

Nanotheranostics takes advantage of nanotechnology-based systems in order to diagnose and treat a specific disease. This approach is particularly relevant for personalized medicine, allowing the detection of a disease at an early stage, to direct a suitable therapy toward the target tissue based on the molecular profile of the altered phenotype, subsequently facilitating disease monitoring and following treatment. A tailored strategy also enables to reduce the off-target effects associated with universal treatments and improve the safety profile of a given treatment. The unique optical properties of gold nanoparticles, their ease of surface modification, and high surface-to-volume ratio have made them central players in this area. By combining imaging, targeting, and therapeutic agents in a single vehicle, these nanoconjugates are (ought to be) an important tool in the clinics. In this review, the multifunctionality of gold nanoparticles as theranostics agents will be highlighted, as well as the requirements before the translation of these nanoplatforms into routine clinical practice.